

Product datasheet for **TL311728V**

LILRB3 Human shRNA Lentiviral Particle (Locus ID 11025)

Product data:

Product Type:	shRNA Lentiviral Particles
Product Name:	LILRB3 Human shRNA Lentiviral Particle (Locus ID 11025)
Locus ID:	11025
Synonyms:	CD85A; HL9; ILT-5; ILT5; LILRA6; LIR-3; LIR3; PIR-B; PIRB
Vector:	pGFP-C-shLenti (TR30023)
Format:	Lentiviral particles
Components:	LILRB3 - Human shRNA lentiviral particles (4 unique 29mer target-specific shRNA, 1 scramble control), 0.5 ml each, >10 ⁷ TU/ml.
RefSeq:	NM_001081450 , NM_006864 , NM_001320960 , NR_135493 , NR_135494 , NR_135495 , NR_135496 , NM_006864.1 , NM_006864.2 , NM_006864.3 , NM_001081450.1 , NM_001081450.2 , BC104993 , BC104993.1 , BC028153 , BC112198
UniProt ID:	O75022
Summary:	This gene is a member of the leukocyte immunoglobulin-like receptor (LIR) family, which is found in a gene cluster at chromosomal region 19q13.4. The encoded protein belongs to the subfamily B class of LIR receptors which contain two or four extracellular immunoglobulin domains, a transmembrane domain, and two to four cytoplasmic immunoreceptor tyrosine-based inhibitory motifs (ITIMs). The receptor is expressed on immune cells where it binds to MHC class I molecules on antigen-presenting cells and transduces a negative signal that inhibits stimulation of an immune response. It is thought to control inflammatory responses and cytotoxicity to help focus the immune response and limit autoreactivity. Multiple transcript variants encoding different isoforms have been found for this gene. [provided by RefSeq, Jul 2008]
shRNA Design:	These shRNA constructs were designed against multiple splice variants at this gene locus. To be certain that your variant of interest is targeted, please contact techsupport@origene.com . If you need a special design or shRNA sequence, please utilize our custom shRNA service .



[View online »](#)

**Performance
Guaranteed:**

OriGene guarantees that the sequences in the shRNA expression cassettes are verified to correspond to the target gene with 100% identity. One of the four constructs at minimum are guaranteed to produce 70% or more gene expression knock-down provided a minimum transfection efficiency of 80% is achieved. Western Blot data is recommended over qPCR to evaluate the silencing effect of the shRNA constructs 72 hrs post transfection. To properly assess knockdown, the gene expression level from the included scramble control vector must be used in comparison with the target-specific shRNA transfected samples.

For non-conforming shRNA, requests for replacement product must be made within ninety (90) days from the date of delivery of the shRNA kit. To arrange for a free replacement with newly designed constructs, please contact Technical Services at techsupport@origene.com. Please provide your data indicating the transfection efficiency and measurement of gene expression knockdown compared to the scrambled shRNA control (Western Blot data preferred).